Clinical Trials Browser

Phase 1 × Refractory Solid Tumors × irinotecan sucrosofate × Clear all

NCT03810742 2023-11-18

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Refractory Solid Tumors